Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors

OBJECTIVE: rhuMAb 2C4 (pertuzumab, RO4368451), a human epidermal growth factor receptor-2 (HER2) targeted antibody that binds to an epitope distinct from trastuzumab, blocks ligand-associated heterodimerization of HER2 with other HER receptor family members. This study evaluated the toxicity, pharma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yamamoto, Noboru, Yamada, Yasuhide, Fujiwara, Yutaka, Yamada, Kazuhiko, Fujisaka, Yasuhito, Shimizu, Toshio, Tamura, Tomohide
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2009
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2661001/
https://ncbi.nlm.nih.gov/pubmed/19261664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyp006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados